— Report will be subject of Midwest CEPAC meeting in April 2021; Open Input now being accepted until September 17, 2020 – BOSTON, August 31, 2020 – The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio) and ciltacabtagene autoleucel (Johnson […]
Read More
08/31/2020
— Document open to public comment until October 13, 2020 – BOSTON, September 22, 2020 – The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of CAR-T treatments and a monoclonal antibody drug for multiple myeloma. All interested stakeholders are encouraged to submit […]
Read More
09/22/2020
BACKGROUND: New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and economic outcomes across all approved regimens. OBJECTIVE: To evaluate the cost-effectiveness of treatments for relapsed and/or refractory MM from a […]
Read More
10/12/2020
June 9, 2016 – The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report and Meeting Summary, titled Treatment Options for Relapsed or Refractory Multiple Myeloma: Effectiveness, Value, and Value-Based Price Benchmarks. The final report, which reviews the comparative clinical effectiveness and value of treatment options for multiple myeloma, incorporates a summary […]
Read More
06/09/2016
Public Comments
Closed